The risk of VTE is highest in the initial period after the diagnosis of malignancy In a new prospective, randomized, double blind clinical trial, Labrie et al confirmed the local beneficial effect of intravaginal DHEA prasterone on the symptoms of mild severe dyspareunia, the most frequent manifestation of genitourinary syndrome in postmenopausal women